Avidity Biosciences, Inc. reported a net loss of $115,773,000 for the three months ended March 31, 2025, an increase from the $68,855,000 net loss in the same period of 2024. Collaboration revenue decreased to $1,573,000 from $3,543,000, while total operating expenses significantly increased to $133,090,000 from $80,730,000. The company's cash, cash equivalents, and marketable securities stood at $1,379,877,000 as of March 31, 2025.

Avidity Biosciences reported a net loss of $102.257 million for Q4 2024, with collaboration revenue of $2.973 million. The company ended 2024 with approximately $1.5 billion in cash, cash equivalents, and marketable securities, positioning it for significant milestones in 2025, including preparing for its first BLA submission.

Avidity Biosciences reported positive del-zota data, initiated the biomarker cohort for the del-brax FORTITUDE study, and is on track with enrollment in the global Phase 3 HARBOR study for del-desiran. The company's cash position is approximately $1.6 billion.

Avidity Biosciences reported positive clinical trial data for del-zota and del-brax, initiated the global Phase 3 HARBOR™ trial for del-desiran, and plans to announce its lead precision cardiology program target in Q4 2024. The company's cash position at the end of the second quarter was approximately $1.3 billion.

Avidity Biosciences reported a cash position of $915.9 million at the end of Q1 2024, following a $400 million private placement. They are advancing their AOC platform and plan to initiate the global Phase 3 HARBOR™ study for del-desiran this quarter. Collaboration revenue was $3.5 million, and research and development expenses were $66.8 million.